Phase III Trial comparing CHOP to PmitCEBO in Good Risk patients with Histologically Aggressive Non-Hodgkin's Lymphoma

Not Applicable

Completed

• Conditions: ymphoma (non-Hodgkin's); Other and unspecified types of non-Hodgkin's lymphoma; Cancer

• Registration Number: ISRCTN23628366
• Lead Sponsor: British National Lymphoma Investigation (BNLI) (UK)

Brief Summary

2009 results in http://www.ncbi.nlm.nih.gov/pubmed/19450285

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2002-08-19
• Study Completion: 2004-12-31
• Last Update Posted: 29 October 2019

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 0

Inclusion Criteria

1. Previously untreated non-Hodgkin's Lymphoma of the following types: follicular large cell lymphoma, diffuse mixed cell lymphoma diffuse large cell lymphoma diffuse immunoblastic lymphoma 0r Revised European/American Lymphoma (REAL) classification: diffuse large B peripheral T cell lymphoma
2. Bulky stage IA and stages IB-IV (Ann Arbour staging system)
3. Age 18-59 years
4. Measurable or evaluable disease
5. Good prognosis, defined as the presence of no more than one of the following adverse features: Stage III/IV Lactic dehydrogenase (LDH) >upper limit of normal Performance status 2-4 (Eastern Cooperative Oncology Group [ECOG]-World Health Organisation [WHO]) Adequate bone marrow function, indicated by Haemoglobin =10 g/dL Neutrophils =2 x 10^9/L Platelets =100 x 10^9/L
6. Written informed consent

Exclusion Criteria

Does not meet inclusion criteria

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ot provided at time of registration

Secondary Outcome Measures

Name	Time	Method
ot provided at time of registration